IDL Diagnostics (IDLDX) Q4 2025 earnings summary

Executive summary

• Achieved record quarterly revenue in Q4 2025, the highest in company history, driven by strong urology segment growth and strategic execution.

• Urology segment sales volume increased by over 16% year-over-year, aligning with strategic focus.

• First commercial TPS CLIA order from Japan for the Chinese market, marking progress in automated platforms.

• Strategic initiatives included a name change, IFRS adoption, and deepened partnership with Concile GmbH.

Financial highlights

• Q4 2025 net sales: SEK 16,303 thousand (up from SEK 15,364 thousand in Q4 2024).

• Full-year 2025 net sales: SEK 53,108 thousand (down from SEK 57,436 thousand in 2024).

• Q4 2025 operating loss: SEK -1,421 thousand (Q4 2024: SEK 667 thousand profit).

• Full-year 2025 operating loss: SEK -11,996 thousand (2024: SEK -3,823 thousand).

• Q4 2025 gross margin: 59.1% (Q4 2024: 54.0%). Full-year gross margin: 52.2% (2024: 54.9%).

• Cash and cash equivalents at year-end: SEK 36,574 thousand (2024: SEK 47,785 thousand).

Outlook and guidance

• Entering 2026 with strong order intake and favorable conditions for continued growth.

• Focus on expanding in Indonesia and leveraging the Concile partnership for broader product offerings.

• Plans to launch TK 210 on automated platforms in 2026, building on TPS CLIA progress.

• Market for cancer diagnostics projected to grow at a 6% CAGR through 2034.